
    
      The endpoints of the study are

        1. To validate the prognostic significance of OPN in H&N and lung cancer patients and to
           monitor its level during active therapy and follow up for cancer surveillance.

        2. To identify a gene and protein signature for hypoxia in H&N and lung cancer patients.
    
  